LDS/Medical Tests/Opioid-use Disorder Pain Management Genotyping Panel

Opioid-use Disorder Pain Management Genotyping Panel

Pain management is one of the major aims of medical treatment and the opioids are commonly employed in managing pain. Opioids are both endogenous (endorphins and endogenous morphine) and exogenous: either as prescription medications (morphine, oxycodone, hydrocodone, codeine, fentanyl tramadol, buprenorphine, methodine, dextromethorphan, meperidine) or illegal drugs (heroin plus the prescribed drugs used illicitly).

In reducing pain, opioids bind primarily to mu opioid receptors present in brain, and spinal cord. Presynaptically, opioids act to block calcium channels in afferent nociceptive nerves inhibiting the release of substance P and glutamate. Postsynaptically, opioids open potassium channels which hyperpolarize neuron cell membranes thereby requiring an increased reaction potential to transmit nociceptive signals. Supraspinally, opioids act in the areas of the brain to further moderate nociception. These areas include the locus ceruleus, nucleus raphe magnus, periaqueductal gray, medial thalamus, and limbic structures.

The intake of exogenous opioids causes an incredible state of euphoria along with pain relief during medical treatment. In patients with chronic pain, long term opioid use will invariably lead to physical dependence, drug tolerance, withdrawal symptoms upon cessation, and various other side effects. In some patients, chronic use may develop into full addiction and opiate use disorder (OUD) which tends to be a chronic relapsing condition with significant socioeconomic consequences. Management of chronic pain with opioids must balance the need for pain relief with the risk of developing dependence and/or OUD. The personal and public health costs of OUD are enormous; in 2016, 26.8 million people were estimated to be living with OUD worldwide, with more than 100,000 opioid overdose deaths annually, including more than 47,000 in the United States.

Importantly, polymorphisms in the human genome have been found to influence the amounts of opioids required for pain alleviation. Numerous gene polymorphisms interfere with the action of opioids and therefore, screening for such polymorphisms with a comprehensive gene panel may be beneficial in determining the type and amount of opioid required for the desired effect. Although it depends on the laboratory and the clinical indication, panels use single nucleotide polymorphism detection to evaluate the most common pain management interfering genes: ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRD1, and OPRK1.

ABCB1 – The ATP binding cassette subfamily B member 1 gene located on chromosome 7q21.12, encodes membrane-associated protein of the superfamily of ATP-binding cassette (ABC) transporters. TT homozygous patients have significantly lower levels of cumulative opioid consumption than the CC homozygous genotype.

COMT - Catecholamine-O-methyltransferase gene located on chromosome 22q11.2, encodes the COMT protein. COMT metabolizes biogenic amines such as dopamine, adrenaline, and norepinephrine, hence its activity influences opioid behavior.

DAT1 - Dopamine transporter 1 gene code DAT, a protein essential for the clearance of DA from the synapse. Substance use disorders have been linked to DAT1 polymorphisms, which could provide insight into their functional implications on DA signaling in addiction. Evidence suggests that the number of VNTR in OUD patients affects their treatment response.

DRD1 - D1Rs are important mediators of several reward-related processes, coded by DRD1 gene. D1R function is important in OUD because DA release generated by opioid-induced MOP receptor activation indirectly stimulates D1Rs and associated reward circuitry. Several studies show that DRD1 variations are linked to the length of time it takes to get from initial usage to opioid dependency. The duration of transition from first use to dependence is clinically significant; individuals who go from first use to dependence more quickly have poorer treatment results and more severe OUD.

DRD2 - The genetic studies suggest a role of DRD2 polymorphisms in treatment response in OUD; however, they remain inconsistent and difficult to replicate.

MTHFR - Methylenetetrahydrofolate reductase converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, and 5-methyltetrahydrofolate. Pain relievers have a poor or restricted response to MTHFR.

HTTLPR -The serotonin transporter gene is encoded by the HTTLPR gene. Healthy participants with the triallelic 5-HTTLPR genotype coding for low 5-HTT expression (SA/SA and SA/LG), compared to those homozygous for the 5-HTTLPR LA allele, had a superior analgesic effect from a short-acting opioid medication.

MUOR - The OPRM1-encoded mu-opioid receptor (MOR) governs the analgesic response to pain and also influences the rewarding effects of several abused substances, including opioids, nicotine, and alcohol. The polymorphism of gene OPRM1, c.118A>G; in homozygous G/G genotype is consistent with decreased sensitivity to opioid agonists and increased sensitivity to opioid antagonist, but in heterozygous G/A or homozygous A/A individual may require higher or frequent doses of opioid receptor agonists to achieve adequate pain control and more likely to respond to opioid antagonist.

  • To determine the type and dose of opioid drugs for pain management
  • To evaluate risk of opioid dependence
  • To manage opioid addiction disorder

The interpretation of this testing is complex given the multiple genetic and non-genetic factors that interact in opioid metabolism.

Positive – Risk of opioid-use disorder

Negative – No risk of opioid-use disorder

Negative for tested gene variations

Mutliplex , Real-time PCR (ARMS), Next Generation Sequencing, Sanger Sequencing.

Whole blood (EDTA; 2 ml), buccal swab or other germline tissue samples.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
Urine drugs screen with Urine drug confirmation.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login